Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targ...

Full description

Bibliographic Details
Main Authors: Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastián Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean O’Donnell, Filippo de Marinis
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-42900-4

Internet

https://doi.org/10.1038/s41467-023-42900-4

Similar Items